Good morning, you're tuned in to Markets Desk.
The GLP-one weight loss drug race is moving from the injectable market into pill form, and two pharma giants are squaring up for what could be a defining commercial battle. Novo Nordisk and Eli Lilly are both positioning oral GLP-one therapies ahead of anticipated Medicare coverage, a development that would open the senior population as a massive new patient base. The stakes here are enormous — we're talking about tens of millions of potential enrollees and the kind of recurring prescription revenue that reshapes a company's earnings profile for a decade.
Shifting to managed care, Elevance Health investors should note the company will trade ex-dividend on June tenth, twenty twenty six, with a quarterly payout of one dollar and seventy-two cents per share. Against a recent stock price of four hundred thirteen dollars and seven cents, that's a modest but steady yield — a signal that Elevance continues prioritizing shareholder returns even as the broader health insurance sector navigates regulatory and reimbursement headwinds.
Meanwhile, Galmed Pharmaceuticals is taking a sharp hit today, falling more than sixteen percent after announcing a deal to acquire Colospan, a commercial-stage medical device firm focused on colorectal surgery. Markets are clearly skeptical about the strategic fit and the capital commitment, sending a pointed message that investors want clarity on how this pivot toward a GI-focused platform actually creates value.
That's the tape. Markets Desk, signing off the floor.
